S-1/A: AIM ImmunoTech Launches $12M Rights Offering Amid Clinical Progress

AIM ImmunoTech Inc. announced a non-transferable rights offering to raise up to $12 million through the sale of units comprising Series G Convertible Preferred Stock and warrants, while providing updates on its Ampligen clinical programs.

Summary

• AIM ImmunoTech is conducting a non-transferable rights offering to raise up to $12 million in gross proceeds by selling up to 12,000 Units.
• Each Unit is priced at $1,000 and consists of one share of Series G Convertible Preferred Stock and 1,492 warrants to purchase common stock.
• The Preferred Stock is convertible into common stock at an initial price of $1.34 per share, and each warrant is exercisable for one common share at $1.34 per share for five years.
• Net proceeds from the offering are estimated at approximately $10.65 million, assuming full subscription, and an additional $23.99 million could be raised if all warrants are exercised for cash.
• Proceeds will be used for general corporate purposes, including clinical trial expenses for prospective Phase 2/3 pancreatic cancer trials, manufacturing, and repayment of existing debt obligations.
• The offering is on a 'best-efforts' basis with no minimum amount of proceeds required to close, and no standby purchase agreement is in place.
• The company reported positive mid-year safety and efficacy updates from the DURIPANC Phase 1b/2 trial for late-stage pancreatic cancer, with 21% of subjects showing progression-free survival greater than 6 months and 64% overall survival greater than 6 months.
• A Phase 2 trial for recurrent platinum-sensitive ovarian cancer combining Ampligen, pembrolizumab, and cisplatin showed an Objective Response Rate (ORR) of 50% (5 complete responses, 7 partial responses out of 24 evaluable patients).
• The Phase 2 study (AMP-518) for post-COVID conditions met its enrollment target of 80 subjects, with final clinical study results posted in January 2025 supporting Ampligen as a potential therapeutic for moderate-to-severe post-COVID fatigue.
• An open-label expanded access protocol for ME/CFS and Post-COVID conditions showed clinically significant decreases in fatigue and improved cognition in preliminary results from the first four Post-COVID patients.

Sentiment

Score: 3

Explanation: The filing presents a mixed bag of promising clinical updates for Ampligen in various indications, which are positive for the company's long-term potential. However, these positives are significantly overshadowed by the immediate and substantial financial challenges, including negative net tangible book value, NYSE American listing non-compliance, and the highly dilutive, 'best-efforts' nature of the capital raise with no minimum. The suspension of a key pancreatic cancer trial also adds a negative operational note. The overall sentiment is cautious to negative due to the pressing financial risks and dilution.

Positives

• Positive mid-year safety and efficacy update from the DURIPANC Phase 1b/2 trial for late-stage pancreatic cancer, with 21% of subjects achieving PFS >6 months and 64% OS >6 months.
• Successful interim data from a Phase 2 trial for recurrent platinum-sensitive ovarian cancer, demonstrating an Objective Response Rate (ORR) of 50% (5 complete responses, 7 partial responses).
• Final clinical study results from the AMP-518 Phase 2 trial for post-COVID conditions support Ampligen as a potential therapeutic for moderate-to-severe fatigue.
• Preliminary positive results from an open-label expanded access protocol for ME/CFS and Post-COVID conditions, showing clinically significant decreases in fatigue and improved cognition.
• The company is actively pursuing a study for a potential avian influenza combination therapy of Ampligen and AstraZeneca's FluMist, building on previous promising preclinical and clinical research.

Negatives

• The rights offering is on a 'best-efforts' basis with no minimum amount of proceeds necessary to close, meaning the company may raise substantially less than the target $12 million.
• Existing stockholders and participating securities holders who do not fully exercise their subscription rights will experience significant dilution.
• Purchasers in the rights offering will suffer immediate and substantial dilution in the net tangible book value of common stock (dilution of $1.12 per share for new purchasers).
• The company's net tangible book value as of September 30, 2025, was negative $8,117,686, or negative $2.94 per share.
• AIM ImmunoTech is not in compliance with NYSE American's stockholders' equity listing requirement (stockholders' deficit of approximately negative $6.1 million as of September 30, 2025), facing a delisting risk if compliance is not regained by June 11, 2026.
• There is no public trading market for the Series G Convertible Preferred Stock or the Warrants, and the company does not intend to apply for their listing, limiting liquidity for these new securities.
• The Phase 2 study for locally advanced or metastatic late-stage pancreatic cancer was placed on hold and suspended in February 2025, pending additional data from the DURIPANC trial, indicating a delay in this specific program.

Risks

• Management will have broad discretion over the use of net proceeds, and funds may not be invested successfully, potentially harming the business.
• Significant dilution for stockholders and securities holders who do not fully exercise their Subscription Rights, and immediate dilution in net tangible book value for purchasers.
• The rights offering has no minimum offering amount, meaning the company may raise insufficient capital to meet business objectives, increasing investor risk.
• The offering may cause the trading price of common stock to decrease due to the subscription price and potential future sales of shares from conversions/exercises.
• Holders of Preferred Stock and Warrants will have no common stockholder rights until conversion or exercise, and prior to conversion, Preferred Stock holders have limited voting rights.
• The company may terminate the rights offering at any time, with obligations limited to returning subscription monies without interest.
• The Subscription Price is not an indication of the fair value of the common stock and does not necessarily bear a relationship to established criteria for value.
• Failure to timely act and follow subscription instructions may result in rejection of subscription rights.
• Subscribers may not receive all the units for which they subscribe due to proration if the offering is oversubscribed or due to beneficial ownership limitations (19.99% of outstanding common stock).
• Personal checks for payment may not clear in time, leading to rejection of subscription.
• Receipt of Subscription Rights may be treated as a taxable distribution if deemed part of a disproportionate distribution under Section 305 of the Code.
• Proposed changes in U.S. tax law may adversely impact the company and the value of its securities.
• Exercising Subscription Rights limits the ability to engage in certain hedging transactions.
• Subscription Rights are non-transferable, meaning no market exists to realize their value directly.
• No public market exists or is expected to develop for the Preferred Stock or Warrants, limiting resale opportunities.
• The market price of common stock may never exceed the exercise price of the Warrants, causing them to expire worthless.
• The dealer-manager is not underwriting or placing the securities, and the offering may not be successful despite their services.
• Unexercised Warrants may have no value in a bankruptcy or reorganization proceeding.
• The company may amend or modify the terms of the rights offering at any time prior to expiration.
• The company is not in compliance with NYSE American continued listing requirements (stockholders' equity below $6 million minimum), risking delisting which could severely impact market price, liquidity, and ability to raise capital.
• Anti-takeover provisions in the Certificate of Incorporation and Bylaws, and Delaware law, could discourage or make it more difficult to effect changes in management or control.

Future Outlook

The company intends to prioritize clinical work in trials authorized by the FDA or EMA that support potential future New Drug Applications (NDAs). It plans to use the proceeds from the rights offering to fund clinical trial expenses, particularly for prospective Phase 2/3 pancreatic cancer trials, and manufacturing expenses. The company is also exploring Ampligen's antiviral activities and potential use as a prophylactic or treatment for existing and new viruses, and as a vaccine adjuvant for influenza, including avian influenza. The pancreatic cancer study (not DURIPANC) may be redesigned or amended pending additional data. The company anticipates not having current and accumulated earnings and profits through the end of 2025.

Management Comments

• Our board of directors is making no recommendation regarding your exercise of the Subscription Rights.
• You should carefully consider whether to exercise your Subscription Rights before the expiration date.
• You may not revoke or revise any exercises of Subscription Rights once made.
• Our management will have broad discretion as to the use of the net proceeds from this Rights Offering and could use them for purposes other than those contemplated at the time of commencement of this Rights Offering.

Industry Context

AIM ImmunoTech operates in the immuno-pharma sector, focusing on nucleic acids and natural interferon to treat cancers, viral diseases, and immune-deficiency disorders. Its flagship product, Ampligen, is being developed for globally important conditions, aligning with the broader industry trend of leveraging immune responses for therapeutic benefit. The company's focus on pancreatic cancer, a notoriously difficult-to-treat malignancy, and its exploration of antiviral applications, including for avian influenza and post-COVID conditions, positions it within high-need areas of medical research. The use of checkpoint inhibitors in combination therapies reflects a common strategy in modern oncology to enhance treatment efficacy.

Comparison to Industry Standards

• The Netherlands study for Ampligen in pancreatic cancer generated statistically significant data indicating extended survival well beyond the Standard of Care (SOC), suggesting a potential improvement over existing treatments.
• The DURIPANC study combining Ampligen with AstraZeneca's Imfinzi (durvalumab) for late-stage pancreatic cancer is a common industry approach of combining novel immunotherapies with established checkpoint inhibitors to improve outcomes.
• The 50% Objective Response Rate (ORR) in the Phase 2 ovarian cancer trial (Ampligen + pembrolizumab + cisplatin) is a strong indicator of efficacy for recurrent platinum-sensitive ovarian cancer, a challenging indication, and compares favorably to historical response rates for single-agent or less intensive combination chemotherapies.
• The company's pursuit of Ampligen as a vaccine adjuvant for influenza, including avian influenza, in combination with AstraZeneca's FluMist, aligns with industry efforts to enhance vaccine effectiveness and broaden protection against emerging viral threats.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Existing shareholders face significant dilution if they do not participate in the rights offering. Participating shareholders will also experience immediate dilution in net tangible book value. All shareholders are exposed to the risk of NYSE American delisting, which could severely impact stock price and liquidity.
• **Potential Investors**: New investors face high risk due to the company's negative net tangible book value, NYSE American non-compliance, and the 'best-efforts' nature of the offering. The lack of a public market for the Preferred Stock and Warrants also limits liquidity.
• **Employees**: Continued operations and clinical trial funding, if successful, could provide stability, but financial distress and delisting risks could create uncertainty.
• **Creditors**: The company intends to allocate a portion of the net proceeds to repay existing debt obligations, which would be positive for creditors.
• **Patients/Medical Community**: Progress in clinical trials for pancreatic cancer, ovarian cancer, ME/CFS, and post-COVID conditions, if successful, could lead to new therapeutic options for high-unmet-need diseases.

Next Steps

• The Rights Offering is expected to expire on or about February 23, 2026, unless extended.
• The company will close on subscriptions as soon as practicable after the expiration date.
• The suspended Phase 2 pancreatic cancer study may be redesigned or amended, pending additional data from the ongoing DURIPANC clinical trial.
• Enrollment and dosing are ongoing in Phase 2 of the DURIPANC study for late-stage pancreatic cancer.
• The company intends to pursue a study of a potential avian influenza combination therapy of Ampligen and AstraZeneca's FluMist.
• The company is seeking collaborative grants from government and industry to defray the cost of the avian influenza study.
• The company must increase its stockholders' equity to at least $6 million to regain compliance with NYSE American listing rules by June 11, 2026.

Key Dates

Recommendation

For existing investors, the recommendation is 'hold' with extreme caution. While there are promising clinical updates for Ampligen in various high-need indications (pancreatic cancer, ovarian cancer, post-COVID conditions), these are early-stage and long-term. The immediate financial situation is critical, marked by negative net tangible book value, a significant stockholders' deficit, and non-compliance with NYSE American listing requirements, which poses a substantial delisting risk. The rights offering, while necessary for capital, is highly dilutive, on a 'best-efforts' basis with no minimum, and introduces illiquid preferred stock and warrants. Existing investors who believe in the long-term clinical potential might consider participating to mitigate dilution, but this involves significant additional capital commitment and risk. For new investors, the high risk profile, coupled with the immediate dilution and financial instability, makes it difficult to recommend a 'buy' at this stage. The company needs to demonstrate successful capital raise and progress towards NYSE compliance before it becomes a more attractive investment.

Keywords

Rights Offering, Preferred Stock, Warrants, Dilution, Capital Raise, Pancreatic Cancer, Ovarian Cancer, Post-COVID Conditions, ME/CFS, Avian Influenza, Ampligen, Immuno-oncology, Antiviral, NYSE American Delisting, Biotechnology, Pharmaceuticals